Public Profile

Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has established itself as a leader in the development and commercialisation of innovative therapeutics, particularly in the areas of pain management and critical care. Cumberland's core products, including Acetadote® and Vaprisol®, are distinguished by their unique formulations and targeted applications, addressing significant medical needs. With a commitment to improving patient outcomes, the company has achieved notable milestones, including successful product launches and strategic partnerships. Cumberland Pharmaceuticals continues to strengthen its market position through a focus on research and development, ensuring its offerings remain at the forefront of the healthcare landscape.

DitchCarbon Score

How does Cumberland Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

Cumberland Pharmaceuticals Inc.'s score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

Let us know if this data was useful to you

Cumberland Pharmaceuticals Inc.'s reported carbon emissions

Cumberland Pharmaceuticals Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific climate commitments outlined in their reduction initiatives. As such, there are no reported figures for their carbon emissions, including Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate strategy or reporting practices. Without specific targets or commitments, it is unclear how Cumberland Pharmaceuticals plans to address its carbon footprint or contribute to broader climate goals within the pharmaceutical industry.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Cumberland Pharmaceuticals Inc.'s primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Cumberland Pharmaceuticals Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Cumberland Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

ANI Pharmaceuticals, Inc.

US
Chemicals nec
Updated about 2 months ago

Melinta Therapeutics

US
Health and social work services (85)
Updated about 2 months ago

Supernus Pharmaceuticals, Inc.

US
Chemicals nec
Updated about 2 months ago

Aquestive Therapeutics, Inc.

US
Chemicals nec
Updated 6 days ago

Par Pharmaceutical

US
Chemicals nec
Updated 3 months ago

Nabriva Therapeutics plc

IE
Health and social work services (85)
Updated about 1 month ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers